Literature DB >> 27855803

Long-Term Outcomes in Patients With Aortic Regurgitation and Preserved Left Ventricular Ejection Fraction.

Amgad Mentias1, Ke Feng1, Alaa Alashi1, L Leonardo Rodriguez1, A Marc Gillinov1, Douglas R Johnston1, Joseph F Sabik1, Lars G Svensson1, Richard A Grimm1, Brian P Griffin1, Milind Y Desai2.   

Abstract

BACKGROUND: Chronic severe aortic regurgitation (AR) imposes significant volume and pressure overload on the left ventricle (LV), but such patients typically remain in an asymptomatic state for a very long time.
OBJECTIVES: This study sought to examine long-term outcomes in a contemporary group of patients with grade III+ chronic AR and preserved left ventricular ejection fraction (LVEF) and the value of aortic valve (AV) surgery on long-term survival. We also wanted to reassess the threshold of LV dimension, beyond which mortality significantly increases.
METHODS: The authors studied 1,417 such patients (mean 54 ± 16 years of age, 75% men) seen between 2002 and 2010. Clinical data were obtained and Society of Thoracic Surgeons (STS) score was calculated. The primary endpoint was mortality.
RESULTS: Mean STS score was 5.5% ± 8%, and mean LVEF was 57 ± 4%, whereas 1,228 patients (87%) were asymptomatic, and 93 patients (7%) had indexed LV end-systolic dimension (iLVESD) ≥2.5 cm/m2. At 6.6 ± 3 years, 933 patients (66%) underwent AV surgery (36% isolated AV surgery, 16% concomitant coronary bypass, and 58% aortic replacement), and 262 patients (19%) died. In-hospital postoperative mortality was 2% (0.6% in isolated AV surgery). On multivariate Cox survival analysis, compared to the group of iLVESD <2.5 cm/m2 and no AV surgery, the 2 groups of iLVESD <2.5 cm/m2 with AV surgery and iLVESD ≥2.5 cm/m2 with AV surgery were associated with improved survival (hazard ratios: 0.62 and 0.42, respectively; both p < 0.01). Survival of patients who underwent AV surgery was similar to that of an age- and sex-matched U.S. population with 96% of deaths occurring in those with iLVESD <2.5 cm/m2.
CONCLUSIONS: At a high-volume experienced center, patients with grade III or greater AR and preserved LVEF demonstrated significantly improved long-term survival following AV surgery. The risk of death significantly increased at a lower LV dimension threshold than previously described.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  aortic valve surgery; indexed left ventricular end-systolic dimension; mortality; outcomes

Mesh:

Year:  2016        PMID: 27855803     DOI: 10.1016/j.jacc.2016.08.045

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

1.  Phase-Contrast Magnetic Resonance Quantification of Aortic Regurgitation in Patients With Turbulent Aortic Flow.

Authors:  Elizabeth Lee; Blair Richards; Jimmy C Lu; Maryam Ghadimi Mahani; Adam L Dorfman; Sowmya Balasubramanian; Prachi P Agarwal
Journal:  J Comput Assist Tomogr       Date:  2019 Mar/Apr       Impact factor: 1.826

2.  Outcomes of Aortic Valve Replacement for Chronic Aortic Insufficiency: Analysis of the Society of Thoracic Surgeons Database.

Authors:  Christopher T Ryan; Ayman Almousa; Rodrigo Zea-Vera; Qianzi Zhang; Christopher I Amos; Joseph S Coselli; Todd K Rosengart; Ravi K Ghanta
Journal:  Ann Thorac Surg       Date:  2021-04-25       Impact factor: 4.330

Review 3.  [ESC/EACTS guidelines 2021 on the management of valvular heart diseases : What are the most important innovations?]

Authors:  F S Nettersheim; S Baldus
Journal:  Herz       Date:  2021-10-05       Impact factor: 1.443

4.  Outcomes in Asymptomatic Severe Aortic Stenosis With Preserved Ejection Fraction Undergoing Rest and Treadmill Stress Echocardiography.

Authors:  Chetan P Huded; Ahmad Masri; Kenya Kusunose; Andrew L Goodman; Richard A Grimm; A Marc Gillinov; Douglas R Johnston; L Leonardo Rodriguez; Zoran B Popovic; Lars G Svensson; Brian P Griffin; Milind Y Desai
Journal:  J Am Heart Assoc       Date:  2018-04-12       Impact factor: 5.501

5.  New Imaging Markers of Clinical Outcome in Asymptomatic Patients with Severe Aortic Regurgitation.

Authors:  Radka Kočková; Hana Línková; Zuzana Hlubocká; Alena Pravečková; Andrea Polednová; Lucie Súkupová; Martin Bláha; Jiří Malý; Eva Honsová; David Sedmera; Martin Pěnička
Journal:  J Clin Med       Date:  2019-10-11       Impact factor: 4.241

6.  Reduced left ventricular contractility, increased diastolic operant stiffness and high energetic expenditure in patients with severe aortic regurgitation without indication for surgery.

Authors:  Jan-Christian Reil; Gert-Hinrich Reil; Nora Hecker; Vasco Sequeira; Jeffrey S Borer; Ulrich Stierle; Daniel Lavall; Christoph Marquetand; Claudia Busch; Johannes Patzelt; Matthias Heringlake; Hans-Joachim Schäfers; Hans-Hinrich Sievers; Stephan Ensminger; Anas Aboud
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-01-01

7.  Long-Term Outcomes in Patients With Mixed Aortic Valve Disease and Preserved Left Ventricular Ejection Fraction.

Authors:  Nicolas Isaza; Milind Y Desai; Samir R Kapadia; Amar Krishnaswamy; L Leonardo Rodriguez; Richard A Grimm; Julijana Z Conic; Yoshihito Saijo; Eric E Roselli; A Marc Gillinov; Douglas R Johnston; Lars G Svensson; Brian P Griffin; Zoran B Popović
Journal:  J Am Heart Assoc       Date:  2020-03-24       Impact factor: 5.501

8.  Abnormal cisatracurium pharmacodynamics and pharmacokinetics among patients with severe aortic regurgitation during anesthetic induction.

Authors:  Xiaocong Huang; Lei Chen; Yujing Cai; Jinfeng Wei; Lina Lin; Jie Sun; Xuemei Peng; Sheng Wang
Journal:  BMC Anesthesiol       Date:  2020-01-22       Impact factor: 2.217

Review 9.  Imaging assessment of mitral and aortic regurgitation: current state of the art.

Authors:  Richard Paul Steeds; Saul G Myerson
Journal:  Heart       Date:  2020-08-17       Impact factor: 5.994

10.  Myocardial Scar and Mortality in Chronic Aortic Regurgitation.

Authors:  Maan Malahfji; Alpana Senapati; Bhupendar Tayal; Duc T Nguyen; Edward A Graviss; Sherif F Nagueh; Michael J Reardon; Miguel Quinones; William A Zoghbi; Dipan J Shah
Journal:  J Am Heart Assoc       Date:  2020-11-26       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.